Compare · MRNA vs TCBP
MRNA vs TCBP
Side-by-side comparison of Moderna Inc. (MRNA) and TC BioPharm (Holdings) plc (TCBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TCBP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $87.10B.
- MRNA has hit the wire 15 times in the past 4 weeks while TCBP has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for TCBP).
- Company
- Moderna Inc.
- TC BioPharm (Holdings) plc
- Price
- -
- -
- Market cap
- $87.10B
- -
- 1M return
- -1.01%
- -
- 1Y return
- +769.75%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2022
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 0
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
TC BioPharm (Holdings) plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Latest TCBP
- TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
- SEC Form 6-K filed by TC BioPharm (Holdings) plc
- TCBP Announces Transition from Nasdaq to OTC Markets
- TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
- TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
- TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
- TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
- SEC Form 6-K filed by TC BioPharm (Holdings) plc
- TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
- TCBP to Implement ADS Ratio Change